Desuden var reduktionerne i HbA1c og FPG for sitagliptin, sammenlignet med placebo, generelt de samme som dem, der er observeret i andre monoterapiundersøgelser hos patienter med normal nyrefunktion (se afsnit 5. 2).
In addition, the reductions in HbA1c and FPG with sitagliptin compared to placebo were generally similar to those observed in other monotherapy studies in patients with normal renal function (see section 5.2).